Childhood Kidney Diseases

  • 제24권1호
  • /
  • Pages.47-52
  • /
  • 2020
  • /
  • 2384-0242(pISSN)
  • /
  • 2384-0250(eISSN)
대한소아신장학회 (Korean Society of Pediatric Nephrology)
권호 표지
DOI QR코드

DOI QR Code

Pneumocystis Pneumonia after Kidney Transplantation in Children

  • Hwang, Soojin (Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine) ;
  • Jung, Jiwon (Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine) ;
  • Lee, Joo Hoon (Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine) ;
  • Park, Young Seo (Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine)
  • 투고 : 2020.03.01
  • 심사 : 2020.03.25
  • 발행 : 2020.04.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Pneumocystis pneumonia (PCP) is a rare disease in healthy people but a potentially fatal opportunistic infection by Pneumocystis jirovecii in immunocompromised patients with organ transplantation. We present three cases of PCP after kidney transplantation in pediatric patients. First case was a 4-year-old boy diagnosed with Denys-Drash syndrome and received living-donor kidney transplantation from his mother at age of 1. Second case was a 19-year-old male, with polycystic kidney disease, who received kidney transplantation from his mother at the age of 18. Third case was a 19-year-old female with chronic kidney disease of unknown etiology, who received kidney transplantation from her father at age of 15. These three patients who were on immunosuppressive therapy and completed of routine PCP prophylaxis for 6 months had presented with cough and dyspnea more than 1 year after transplantation. Chest x-ray all showed diffuse haziness of both lung fields, and bronchoalveolar lavage from bronchoscopy revealed Pneumocystisjirovecii infection. All patients showed clinical resolution with intravenous trimethoprim-sulfamethoxazole (TMP-SMX) therapy for at least 3 weeks and had continued secondary prophylaxis for another 6-12 months. This report suggests that clinicians should have suspicion for the possibilities of opportunistic infection such as PCP after kidney transplantation in children.

키워드

참고문헌

  1. Fine RN, Martz K, Stablein D. What have 20 years of data from the North American Pediatric Renal Transplant Cooperative Study taught us about growth following renal transplantation in infants, children, and adolescents with end-stage renal disease? Pediatr Nephrol 2010;25:739-46. https://doi.org/10.1007/s00467-009-1387-3
  2. Neff RT, Jindal RM, Yoo DY, Hurst FP, Agodoa LY, Abbott KC. Analysis of USRDS: incidence and risk factors for Pneumocystis jiroveci pneumonia. Transplantation 2009;88:135-41. https://doi.org/10.1097/TP.0b013e3181aad256
  3. Arichi N, Kishikawa H, Mitsui Y, Kato T, Nishimura K, Tachikawa R, et al. Cluster outbreak of Pneumocystis pneumonia among kidney transplant patients within a single center. Transplant Proc 2009;41:170-2. https://doi.org/10.1016/j.transproceed.2008.10.027
  4. Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 2004;17:770-82, table of contents. https://doi.org/10.1128/CMR.17.4.770-782.2004
  5. Perez-Ordono L, Hoyo I, Sanclemente G, Ricart MJ, Cofan F, Perez-Villa F, et al. Late-onset Pneumocystis jiroveci i pneumonia in solid organ transplant recipients. Transpl Infect Dis 2014;16:324-8. https://doi.org/10.1111/tid.12184
  6. Transplantation EEGoR. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.2.2 Chronic graft dysfunction. Immunological factors (alloimmunity). Nephrol Dial Transplant 2002;17 Suppl 4:8-11.
  7. Kasiske BL, Zeier MG, Chapman JR, Craig JC, Ekberg H, Garvey CA, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 2010;77:299-311. https://doi.org/10.1038/ki.2009.377
  8. Radisic M, Lattes R, Chapman JF, del Carmen Rial M, Guardia O, Seu F, et al. Risk factors for Pneumocystis carinii pneumonia in kidney transplant recipients: a case-control study. Transpl Infect Dis 2003;5:84-93. https://doi.org/10.1034/j.1399-3062.2003.00018.x
  9. Eitner F, Hauser IA, Rettkowski O, Rath T, Lopau K, Pliquett RU, et al. Risk factors for Pneumocystis jiroveci pneumonia (PcP) in renal transplant recipients. Nephrol Dial Transplant 2011;26:2013-7. https://doi.org/10.1093/ndt/gfq689
  10. Yazaki H, Goto N, Uchida K, Kobayashi T, Gatanaga H, Oka S. Outbreak of Pneumocystis jiroveci pneumonia in renal transplant recipients: P. jiroveci is contagious to the susceptible host. Transplantation 2009;88:380-5. https://doi.org/10.1097/TP.0b013e3181aed389
  11. McCaughan JA, Courtney AE. Pneumocystis jiroveci pneumonia in renal transplantation: time to review our practice? Nephrol Dial Transplant 2012;27:13-5. https://doi.org/10.1093/ndt/gfr444
  12. Neofytos D, Hirzel C, Boely E, Lecompte T, Khanna N, Mueller NJ, et al. Pneumocystis jiroveci i pneumonia in solid organ transplant recipients: a descriptive analysis for the Swiss Transplant Cohort. Transpl Infect Dis 2018;20:e12984. https://doi.org/10.1111/tid.12984
  13. Ewald H, Raatz H, Boscacci R, Furrer H, Bucher HC, Briel M. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. Cochrane Database Syst Rev 2015:CD006150.
  14. Gaston RS. Maintenance immunosuppression in the renal transplant recipient: an overview. Am J Kidney Dis 2001;38(6 Suppl 6):S25-35. https://doi.org/10.1053/ajkd.2001.28923
  15. Martin SI, Fishman JA, Practice ASTIDCo. Pneumocystis pneumonia in solid organ transplantation. Am J Transplant 2013;13 Suppl 4:272-9. https://doi.org/10.1111/ajt.12119
  16. Iriart X, Bouar ML, Kamar N, Berry A. Pneumocystis Pneumonia in solid-organ transplant recipients. J Fungi (Basel) 2015;1:293-331. https://doi.org/10.3390/jof1030293